Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2005 1
2006 1
2007 3
2008 6
2009 3
2010 5
2011 7
2012 12
2013 10
2014 12
2015 9
2016 14
2017 13
2018 12
2019 16
2020 13
2021 14
2022 12
2023 15
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Results by year

Filters applied: . Clear all
Page 1
Tofacitinib versus methotrexate in rheumatoid arthritis.
Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, Koncz T, Krishnaswami S, Wallenstein GV, Zang C, Zwillich SH, van Vollenhoven RF; ORAL Start Investigators. Lee EB, et al. N Engl J Med. 2014 Jun 19;370(25):2377-86. doi: 10.1056/NEJMoa1310476. N Engl J Med. 2014. PMID: 24941177 Free article. Clinical Trial.
Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T, Wallenstein GV, Krishnaswami S, Bradley JD, Wilkinson B; ORAL Standard Investigators. van Vollenhoven RF, et al. N Engl J Med. 2012 Aug 9;367(6):508-19. doi: 10.1056/NEJMoa1112072. N Engl J Med. 2012. PMID: 22873531 Free article. Clinical Trial.
Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications.
Taylor PC, Bieber T, Alten R, Witte T, Galloway J, Deberdt W, Issa M, Haladyj E, De La Torre I, Grond S, Wollenberg A. Taylor PC, et al. Among authors: alten r. Adv Ther. 2023 Apr;40(4):1867-1883. doi: 10.1007/s12325-023-02445-w. Epub 2023 Feb 20. Adv Ther. 2023. PMID: 36802049 Free PMC article. Clinical Trial.
Macrophagic Myofasciitis.
Stenzel W, Heppner FL, Goebel HH, Alten RH. Stenzel W, et al. Among authors: alten rh. Dtsch Arztebl Int. 2009 Apr;106(14):248. doi: 10.3238/arztebl.2009.0248a. Epub 2009 Apr 3. Dtsch Arztebl Int. 2009. PMID: 19547641 Free PMC article. No abstract available.
New concepts to reduce glucocorticoid toxicity.
Alten R, Mischkewitz M. Alten R, et al. Joint Bone Spine. 2019 Nov;86(6):715-723. doi: 10.1016/j.jbspin.2018.11.006. Epub 2018 Dec 5. Joint Bone Spine. 2019. PMID: 30528678 Review.
Maximizing the success of biosimilar implementation.
Alten R, Weinbrecht-Mischkewitz M. Alten R, et al. Nat Rev Rheumatol. 2023 Dec;19(12):757-758. doi: 10.1038/s41584-023-01048-7. Nat Rev Rheumatol. 2023. PMID: 37903917 No abstract available.
Clinical trial development for biosimilars.
Alten R, Cronstein BN. Alten R, et al. Semin Arthritis Rheum. 2015 Jun;44(6 Suppl):S2-8. doi: 10.1016/j.semarthrit.2015.04.002. Semin Arthritis Rheum. 2015. PMID: 26058550 Free article. Review.
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases.
Kim H, Alten R, Avedano L, Dignass A, Gomollón F, Greveson K, Halfvarson J, Irving PM, Jahnsen J, Lakatos PL, Lee J, Makri S, Parker B, Peyrin-Biroulet L, Schreiber S, Simoens S, Westhovens R, Danese S, Jeong JH. Kim H, et al. Among authors: alten r. Drugs. 2020 Feb;80(2):99-113. doi: 10.1007/s40265-020-01256-5. Drugs. 2020. PMID: 32002851 Free PMC article. Review.
165 results